Pakistan Steps Up Hepatitis C Elimination Pilot Programme

Pakistan has made notable progress toward eliminating hepatitis C, driven by a combination of national policy reforms, expanded screening, and affordable treatment access. The country’s elimination pilot programmes have evolved into a coordinated national effort that integrates hepatitis services into the primary healthcare system. Despite persistent challenges in data reporting and socioeconomic barriers, Pakistan’s strategy is moving closer to global elimination targets through innovation, partnerships, and evidence-based policymaking.

The Current Landscape of Hepatitis C Elimination in Pakistan

Pakistan’s hepatitis C control landscape reflects years of evolving public health priorities shaped by high disease prevalence and limited early detection systems. The government has transitioned from fragmented provincial initiatives to a unified national framework emphasizing prevention, diagnosis, and treatment.

Overview of National Hepatitis Control Strategies

The evolution of Pakistan’s hepatitis control efforts began with vertical programmes focused on blood safety and awareness campaigns. Over time, these initiatives merged into a broader National Hepatitis Control Programme that aligns with WHO’s global elimination roadmap. Integration within the national health system now allows hepatitis services—screening, diagnostics, and treatment—to be delivered alongside primary care interventions such as maternal health or tuberculosis control. Coordination between federal and provincial authorities ensures resource allocation follows epidemiological need rather than administrative boundaries, though disparities in implementation remain visible across regions.

Epidemiological Trends and Disease Burden

Recent national surveys estimate that nearly 5% of Pakistan’s adult population is infected with hepatitis C virus (HCV), one of the highest rates globally. Mortality associated with chronic liver disease continues to rise due to late diagnosis and limited historical access to antivirals. Punjab and Sindh provinces bear the heaviest burden, while Balochistan reports lower but under-documented prevalence due to weaker surveillance systems. Behavioral risk factors include unsafe medical injections, unregulated dental practices, and reuse of syringes—issues tied to informal healthcare providers operating outside regulatory oversight.

Advancements in the National Elimination Programme

Pakistan’s elimination programme has entered an acceleration phase marked by decentralization of testing services and improved supply chain management for antiviral drugs. This phase seeks not only case detection but also sustained linkage to care.

Expansion of Screening and Diagnostic Infrastructure

Community-based screening campaigns have scaled up rapidly through mobile units and local health workers trained to identify at-risk populations. Point-of-care testing technologies have shortened diagnostic timelines from weeks to minutes, allowing same-day referral for treatment initiation. Laboratory networks are being strengthened through standardized protocols for viral load testing, while digital registries now track diagnosed cases across districts for better follow-up.

Access to Affordable Antiviral Treatment

Direct-acting antivirals (DAAs) have transformed hepatitis C therapy by achieving cure rates exceeding 95%. Pakistan adopted generic DAA production early through licensing agreements that drastically reduced costs compared with imported brands. Government procurement policies prioritize bulk purchasing under transparent bidding systems to maintain affordability across provinces. Adherence monitoring involves SMS reminders and periodic nurse-led consultations that help sustain treatment completion rates above 80%.

Integration with Primary Healthcare Services

Embedding hepatitis C management within existing primary healthcare channels is essential for long-term sustainability. This integration ensures consistent service delivery even in rural settings where specialist facilities are scarce.

Strengthening Health System Delivery Channels

Primary care centers now serve as entry points for screening and referral under district health authorities’ supervision. Training modules developed by the Ministry of Health equip general practitioners with standardized protocols for diagnosis and patient counseling. However, maintaining quality assurance remains difficult due to uneven facility resources and varying staff competencies between urban and rural clinics.

Role of Digital Health Tools in Service Delivery

Digital transformation supports continuity of care through electronic medical records that track patients from diagnosis to cure confirmation. Telemedicine platforms connect remote clinics with hepatology specialists based in tertiary hospitals, reducing travel costs for patients in isolated areas. Data analytics tools aggregate anonymized patient information to guide resource distribution based on real-time disease trends.

Public Health Partnerships and International Collaboration

Elimination efforts rely heavily on collaboration between domestic institutions and international partners providing technical expertise, funding support, and policy alignment with global frameworks.

Contributions from Global Health Organizations

WHO frameworks define measurable elimination milestones such as 90% reduction in new infections by 2030. Donor-supported pilot projects have strengthened laboratory capacity, introduced infection control training, and supported mass awareness drives targeting high-risk groups like healthcare workers or blood donors. Alignment with Sustainable Development Goals reinforces the link between viral hepatitis control and broader public health equity objectives.

Multi-Sectoral Engagement within Pakistan

Government agencies collaborate closely with universities conducting operational research on transmission patterns, while private pharmaceutical firms contribute through local drug manufacturing initiatives that stabilize supply chains. Community organizations run outreach campaigns promoting safe injection practices and voluntary testing days at workplaces or schools. These partnerships enhance both prevention coverage and public trust in government-led initiatives.

Emerging Challenges in Achieving Elimination Targets

Despite progress, several systemic gaps hinder full realization of elimination goals by 2030. Surveillance weaknesses and social inequities continue to limit programme reach among marginalized populations.

Addressing Gaps in Surveillance and Data Reporting

The surveillance network remains fragmented across provinces using incompatible data systems that impede timely reporting. Underreporting persists because many patients seek care from informal practitioners who rarely document cases officially. Strengthening real-time reporting platforms linked directly to district laboratories could improve accuracy while enabling rapid outbreak response when clusters appear.

Overcoming Socioeconomic Barriers to Care Access

Poverty restricts healthcare-seeking behavior even when free treatment is available due to indirect costs like transportation or lost wages during clinic visits. Stigma surrounding infectious diseases discourages women from seeking testing or follow-up care after positive results. Targeted outreach using female community health workers has shown promise in bridging gender gaps by offering home-based sample collection services.

Future Directions for Sustained Elimination Efforts

Sustaining momentum beyond initial success requires adaptive policy mechanisms that align financial planning with evolving epidemiological realities while encouraging innovation through research investment.

Policy Innovations Supporting Long-Term Success

Policy reforms emphasize integrating hepatitis elimination within universal health coverage schemes so that screening becomes routine rather than campaign-based. Financing models are shifting toward pooled provincial funds supported by social insurance contributions instead of donor dependency. Regulatory improvements focusing on drug quality assurance aim to prevent counterfeit antivirals entering local markets—a recurring issue undermining treatment outcomes.

Research Priorities and Technological Innovation Opportunities

Ongoing research explores simplified diagnostic kits suitable for field use without laboratory infrastructure as well as vaccine candidates targeting multiple HCV genotypes prevalent in South Asia. Artificial intelligence–based modeling tools are being tested to predict transmission hotspots using demographic data combined with mobility patterns extracted from mobile networks. Continuous evaluation loops built into programme design allow policymakers to adjust strategies dynamically as new insights emerge from field operations.

FAQ

Q1: What is Pakistan’s target year for eliminating hepatitis C?
A: The country aims to meet WHO’s 2030 target for eliminating viral hepatitis as a public health threat.

Q2: How effective are direct-acting antivirals used in Pakistan?
A: DAAs achieve cure rates above 95% when administered correctly under national treatment protocols.

Q3: What role do community health workers play?
A: They conduct door-to-door screening, provide counseling on safe practices, and link positive cases with nearby treatment centers.

Q4: Why does underreporting remain a problem?
A: Many people seek help from unregistered practitioners who do not record cases within official surveillance systems.

Q5: Are digital tools improving patient management?
A: Yes, electronic records and telemedicine platforms now allow continuous monitoring even in remote districts where specialists are unavailable.